31 results
Search Results
2. A Collection on the prevention, diagnosis, and treatment of sexually transmitted infections: Call for research papers
- Author
-
Nathalie Broutet, Richard Turner, and Nicola Low
- Subjects
Human Papillomavirus Infection ,Viral Diseases ,medicine.medical_specialty ,Infectious Disease Control ,Urology ,Sexually Transmitted Diseases ,MEDLINE ,lcsh:Medicine ,610 Medicine & health ,ComputingMilieux_LEGALASPECTSOFCOMPUTING ,030204 cardiovascular system & hematology ,Global Health ,Microbiology ,Chlamydia Infection ,03 medical and health sciences ,0302 clinical medicine ,360 Social problems & social services ,Virology ,Epidemiology ,Medicine and Health Sciences ,Global health ,medicine ,Public and Occupational Health ,030212 general & internal medicine ,Transmission risks and rates ,ComputingMilieux_MISCELLANEOUS ,Preventive healthcare ,Cervical cancer ,Genitourinary Infections ,business.industry ,lcsh:R ,Biology and Life Sciences ,HIV diagnosis and management ,General Medicine ,medicine.disease ,Diagnostic medicine ,Cancer treatment ,Editorial ,Infectious Diseases ,Family medicine ,Immunology ,Preventive Medicine ,business ,Viral Transmission and Infection - Abstract
Nicola Low and colleagues announce a call for research papers on sexually transmitted infections, to accompany a Collection on the topic.
- Published
- 2017
3. Bringing Access to the Full Spectrum of Cancer Research: A Call for Papers.
- Author
-
null, null
- Subjects
- *
CANCER research , *CANCER treatment - Abstract
The PLOS Medicine editors issue a call for papers for translational and clinical cancer research papers with strong potential to advance patient care, public policy, or clinical research agendas. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Clinical Implications of Cancer Genomics: A Call for Papers.
- Author
-
null, null and PLOS Medicine Editors
- Subjects
CANCER genetics ,IMMUNOTHERAPY ,CANCER treatment ,CANCER vaccines ,BIOPSY ,CANCER diagnosis ,GENETICS ,HUMAN genome ,MEDICAL research ,NEWSLETTERS ,PUBLISHING ,TUMORS ,GENOMICS - Abstract
In this month's editorial, the PLOS Medicine Editors announce an upcoming Special Issue, with Guest Editors Elaine Mardis and Marc Ladanyi, on actionable advances in research on the cancer genome. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.
- Author
-
Fathallah-Shaykh, Hassan M., DeAtkine, Andrew, Coffee, Elizabeth, Khayat, Elias, Bag, Asim K., Han, Xiaosi, Warren, Paula Province, Bredel, Markus, Fiveash, John, Markert, James, Bouaynaya, Nidhal, and Nabors, Louis B.
- Subjects
OLIGODENDROGLIOMAS ,GLIOMAS ,VOLUME measurements ,PHYSICIANS ,MEDICAL personnel ,TUMOR growth - Abstract
Background: Low-grade gliomas cause significant neurological morbidity by brain invasion. There is no universally accepted objective technique available for detection of enlargement of low-grade gliomas in the clinical setting; subjective evaluation by clinicians using visual comparison of longitudinal radiological studies is the gold standard. The aim of this study is to determine whether a computer-assisted diagnosis (CAD) method helps physicians detect earlier growth of low-grade gliomas.Methods and Findings: We reviewed 165 patients diagnosed with grade 2 gliomas, seen at the University of Alabama at Birmingham clinics from 1 July 2017 to 14 May 2018. MRI scans were collected during the spring and summer of 2018. Fifty-six gliomas met the inclusion criteria, including 19 oligodendrogliomas, 26 astrocytomas, and 11 mixed gliomas in 30 males and 26 females with a mean age of 48 years and a range of follow-up of 150.2 months (difference between highest and lowest values). None received radiation therapy. We also studied 7 patients with an imaging abnormality without pathological diagnosis, who were clinically stable at the time of retrospective review (14 May 2018). This study compared growth detection by 7 physicians aided by the CAD method with retrospective clinical reports. The tumors of 63 patients (56 + 7) in 627 MRI scans were digitized, including 34 grade 2 gliomas with radiological progression and 22 radiologically stable grade 2 gliomas. The CAD method consisted of tumor segmentation, computing volumes, and pointing to growth by the online abrupt change-of-point method, which considers only past measurements. Independent scientists have evaluated the segmentation method. In 29 of the 34 patients with progression, the median time to growth detection was only 14 months for CAD compared to 44 months for current standard of care radiological evaluation (p < 0.001). Using CAD, accurate detection of tumor enlargement was possible with a median of only 57% change in the tumor volume as compared to a median of 174% change of volume necessary to diagnose tumor growth using standard of care clinical methods (p < 0.001). In the radiologically stable group, CAD facilitated growth detection in 13 out of 22 patients. CAD did not detect growth in the imaging abnormality group. The main limitation of this study was its retrospective design; nevertheless, the results depict the current state of a gold standard in clinical practice that allowed a significant increase in tumor volumes from baseline before detection. Such large increases in tumor volume would not be permitted in a prospective design. The number of glioma patients (n = 56) is a limitation; however, it is equivalent to the number of patients in phase II clinical trials.Conclusions: The current practice of visual comparison of longitudinal MRI scans is associated with significant delays in detecting growth of low-grade gliomas. Our findings support the idea that physicians aided by CAD detect growth at significantly smaller volumes than physicians using visual comparison alone. This study does not answer the questions whether to treat or not and which treatment modality is optimal. Nonetheless, early growth detection sets the stage for future clinical studies that address these questions and whether early therapeutic interventions prolong survival and improve quality of life. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: A cluster-randomised trial.
- Author
-
Ndiaye, Jean Louis A., Ndiaye, Youssoupha, Ba, Mamadou S., Faye, Babacar, Ndiaye, Maguette, Seck, Amadou, Tine, Roger, Thior, Pape Moussa, Atwal, Sharanjeet, Beshir, Khalid, Sutherland, Colin, Gaye, Oumar, and Milligan, Paul
- Subjects
AGE ,MALARIA ,AGE groups - Abstract
Background: Seasonal malaria chemoprevention (SMC) is recommended in the Sahel region of Africa for children under 5 years of age, for up to 4 months of the year. It may be appropriate to include older children, and to provide protection for more than 4 months. We evaluated the effectiveness of SMC using sulfadoxine-pyrimethamine plus amodiaquine given over 5 months to children under 10 years of age in Saraya district in south-east Senegal in 2011.Methods and Findings: Twenty-four villages, including 2,301 children aged 3-59 months and 2,245 aged 5-9 years, were randomised to receive SMC with community case management (CCM) (SMC villages) or CCM alone (control villages). In all villages, community health workers (CHWs) were trained to treat malaria cases with artemisinin combination therapy after testing with a rapid diagnostic test (RDT). In SMC villages, CHWs administered SMC to children aged 3 months to 9 years once a month for 5 months. The study was conducted from 27 July to 31 December 2011. The primary outcome was malaria (fever or history of fever with a positive RDT). The prevalence of anaemia and parasitaemia was measured in a survey at the end of the transmission season. Molecular markers associated with resistance to SMC drugs were analysed in samples from incident malaria cases and from children with parasitaemia in the survey. SMC was well tolerated with no serious adverse reactions. There were 1,472 RDT-confirmed malaria cases in the control villages and 270 in the SMC villages. Among children under 5 years of age, the rate difference was 110.8/1,000/month (95% CI 64.7, 156.8; p < 0.001) and among children 5-9 years of age, 101.3/1,000/month (95% CI 66.7, 136.0; p < 0.001). The mean haemoglobin concentration at the end of the transmission season was higher in SMC than control villages, by 6.5 g/l (95% CI 2.0, 11; p = 0.007) among children under 5 years of age, and by 5.2 g/l (95% CI 0.4, 9.9; p = 0.035) among children 5-9 years of age. The prevalence of parasitaemia was 18% in children under 5 years of age and 25% in children 5-9 years of age in the control villages, and 5.7% and 5.8%, respectively, in these 2 age groups in the SMC villages, with prevalence differences of 12.5% (95% CI 6.8%, 18.2%; p < 0.001) in children under 5 years of age and 19.3% (95% CI 8.3%, 30.2%; p < 0.001) in children 5-9 years of age. The pfdhps-540E mutation associated with clinical resistance to sulfadoxine-pyrimethamine was found in 0.8% of samples from malaria cases but not in the final survey. Twelve children died in the control group and 14 in the SMC group, a rate difference of 0.096/1,000 child-months (95% CI 0.99, 1.18; p = 0.895). Limitations of this study include that we were not able to obtain blood smears for microscopy for all suspected malaria cases, such that we had to rely on RDTs for confirmation, which may have included false positives.Conclusions: In this study SMC for children under 10 years of age given over 5 months was feasible, well tolerated, and effective in preventing malaria episodes, and reduced the prevalence of parasitaemia and anaemia. SMC with CCM achieved high coverage and ensured children with malaria were promptly treated with artemether-lumefantrine.Trial Registration: www.clinicaltrials.gov NCT01449045. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
7. Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study.
- Author
-
Hosny, Ahmed, Parmar, Chintan, Coroller, Thibaud P., Grossmann, Patrick, Zeleznik, Roman, Kumar, Avnish, Bussink, Johan, Gillies, Robert J., Mak, Raymond H., and Aerts, Hugo J. W. L.
- Subjects
DEEP learning ,NON-small-cell lung carcinoma ,DIAGNOSTIC imaging ,MEDICAL innovations ,COMPUTED tomography - Abstract
Background: Non-small-cell lung cancer (NSCLC) patients often demonstrate varying clinical courses and outcomes, even within the same tumor stage. This study explores deep learning applications in medical imaging allowing for the automated quantification of radiographic characteristics and potentially improving patient stratification.Methods and Findings: We performed an integrative analysis on 7 independent datasets across 5 institutions totaling 1,194 NSCLC patients (age median = 68.3 years [range 32.5-93.3], survival median = 1.7 years [range 0.0-11.7]). Using external validation in computed tomography (CT) data, we identified prognostic signatures using a 3D convolutional neural network (CNN) for patients treated with radiotherapy (n = 771, age median = 68.0 years [range 32.5-93.3], survival median = 1.3 years [range 0.0-11.7]). We then employed a transfer learning approach to achieve the same for surgery patients (n = 391, age median = 69.1 years [range 37.2-88.0], survival median = 3.1 years [range 0.0-8.8]). We found that the CNN predictions were significantly associated with 2-year overall survival from the start of respective treatment for radiotherapy (area under the receiver operating characteristic curve [AUC] = 0.70 [95% CI 0.63-0.78], p < 0.001) and surgery (AUC = 0.71 [95% CI 0.60-0.82], p < 0.001) patients. The CNN was also able to significantly stratify patients into low and high mortality risk groups in both the radiotherapy (p < 0.001) and surgery (p = 0.03) datasets. Additionally, the CNN was found to significantly outperform random forest models built on clinical parameters-including age, sex, and tumor node metastasis stage-as well as demonstrate high robustness against test-retest (intraclass correlation coefficient = 0.91) and inter-reader (Spearman's rank-order correlation = 0.88) variations. To gain a better understanding of the characteristics captured by the CNN, we identified regions with the most contribution towards predictions and highlighted the importance of tumor-surrounding tissue in patient stratification. We also present preliminary findings on the biological basis of the captured phenotypes as being linked to cell cycle and transcriptional processes. Limitations include the retrospective nature of this study as well as the opaque black box nature of deep learning networks.Conclusions: Our results provide evidence that deep learning networks may be used for mortality risk stratification based on standard-of-care CT images from NSCLC patients. This evidence motivates future research into better deciphering the clinical and biological basis of deep learning networks as well as validation in prospective data. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
8. The current and potential health benefits of the National Health Service Health Check cardiovascular disease prevention programme in England: A microsimulation study.
- Author
-
Mytton, Oliver T., Jackson, Christopher, Steinacher, Arno, Goodman, Anna, Langenberg, Claudia, Griffin, Simon, Wareham, Nick, and Woodcock, James
- Subjects
CARDIOVASCULAR disease prevention ,PUBLIC health ,TREATMENT effectiveness ,ANTIHYPERTENSIVE agents - Abstract
Background: The National Health Service (NHS) Health Check programme was introduced in 2009 in England to systematically assess all adults in midlife for cardiovascular disease risk factors. However, its current benefit and impact on health inequalities are unknown. It is also unclear whether feasible changes in how it is delivered could result in increased benefits. It is one of the first such programmes in the world. We sought to estimate the health benefits and effect on inequalities of the current NHS Health Check programme and the impact of making feasible changes to its implementation.Methods and Findings: We developed a microsimulation model to estimate the health benefits (incident ischaemic heart disease, stroke, dementia, and lung cancer) of the NHS Health Check programme in England. We simulated a population of adults in England aged 40-45 years and followed until age 100 years, using data from the Health Survey of England (2009-2012) and the English Longitudinal Study of Aging (1998-2012), to simulate changes in risk factors for simulated individuals over time. We used recent programme data to describe uptake of NHS Health Checks and of 4 associated interventions (statin medication, antihypertensive medication, smoking cessation, and weight management). Estimates of treatment efficacy and adherence were based on trial data. We estimated the benefits of the current NHS Health Check programme compared to a healthcare system without systematic health checks. This counterfactual scenario models the detection and treatment of risk factors that occur within 'routine' primary care. We also explored the impact of making feasible changes to implementation of the programme concerning eligibility, uptake of NHS Health Checks, and uptake of treatments offered through the programme. We estimate that the NHS Health Check programme prevents 390 (95% credible interval 290 to 500) premature deaths before 80 years of age and results in an additional 1,370 (95% credible interval 1,100 to 1,690) people being free of disease (ischaemic heart disease, stroke, dementia, and lung cancer) at age 80 years per million people aged 40-45 years at baseline. Over the life of the cohort (i.e., followed from 40-45 years to 100 years), the changes result in an additional 10,000 (95% credible interval 8,200 to 13,000) quality-adjusted life years (QALYs) and an additional 9,000 (6,900 to 11,300) years of life. This equates to approximately 300 fewer premature deaths and 1,000 more people living free of these diseases each year in England. We estimate that the current programme is increasing QALYs by 3.8 days (95% credible interval 3.0-4.7) per head of population and increasing survival by 3.3 days (2.5-4.1) per head of population over the 60 years of follow-up. The current programme has a greater absolute impact on health for those living in the most deprived areas compared to those living in the least deprived areas (4.4 [2.7-6.5] days of additional quality-adjusted life per head of population versus 2.8 [1.7-4.0] days; 5.1 [3.4-7.1] additional days lived per head of population versus 3.3 [2.1-4.5] days). Making feasible changes to the delivery of the existing programme could result in a sizable increase in the benefit. For example, a strategy that combines extending eligibility to those with preexisting hypertension, extending the upper age of eligibility to 79 years, increasing uptake of health checks by 30%, and increasing treatment rates 2.5-fold amongst eligible patients (i.e., 'maximum potential' scenario) results in at least a 3-fold increase in benefits compared to the current programme (1,360 premature deaths versus 390; 5,100 people free of 1 of the 4 diseases versus 1,370; 37,000 additional QALYs versus 10,000; 33,000 additional years of life versus 9,000). Ensuring those who are assessed and eligible for statins receive statins is a particularly important strategy to increase benefits. Estimates of overall benefit are based on current incidence and management, and future declines in disease incidence or improvements in treatment could alter the actual benefits observed in the long run. We have focused on the cardiovascular element of the NHS Health Check programme. Some important noncardiovascular health outcomes (e.g., chronic obstructive pulmonary disease [COPD] prevention from smoking cessation and cancer prevention from weight loss) and other parts of the programme (e.g., brief interventions to reduce harmful alcohol consumption) have not been modelled.Conclusions: Our model indicates that the current NHS Health Check programme is contributing to improvements in health and reducing health inequalities. Feasible changes in the organisation of the programme could result in more than a 3-fold increase in health benefits. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. Data sharing in clinical trials: An experience with two large cancer screening trials.
- Author
-
Zhu, Claire S., Pinsky, Paul F., Moler, James E., Kukwa, Andrew, Mabie, Jerome, Rathmell, Joshua M., Riley, Tom, Prorok, Philip C., and Berg, Christine D.
- Subjects
INFORMATION sharing ,CLINICAL trials ,MEDICAL screening ,CANCER diagnosis ,MEDICAL databases - Abstract
Paul Pinsky of the US National Cancer Institute and colleagues describe the implementation and outcomes of web-based data sharing from the PLCO and NLST cancer screening trials. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
- Author
-
Hamblin, Angela, Wordsworth, Sarah, Fermont, Jilles M., Page, Suzanne, Kaur, Kulvinder, Camps, Carme, Kaisaki, Pamela, Gupta, Avinash, Talbot, Denis, Middleton, Mark, Henderson, Shirley, Cutts, Anthony, Vavoulis, Dimitrios V., Housby, Nick, Tomlinson, Ian, Taylor, Jenny C., and Schuh, Anna
- Subjects
TUMOR genetics ,GENE expression ,GENETIC regulation ,GENOMICS ,LUNG cancer diagnosis ,LUNG cancer treatment ,MELANOMA diagnosis ,MELANOMA treatment ,CLINICAL trials ,COMPARATIVE studies ,LONGITUDINAL method ,COLON tumors ,LUNG cancer ,RESEARCH methodology ,MEDICAL cooperation ,NATIONAL health services ,MELANOMA ,PATHOLOGY ,RESEARCH ,RESEARCH funding ,RECTUM tumors ,EVALUATION research ,RETROSPECTIVE studies ,SEQUENCE analysis ,ECONOMICS ,DIAGNOSIS ,TUMOR treatment - Abstract
Background: Single gene tests to predict whether cancers respond to specific targeted therapies are performed increasingly often. Advances in sequencing technology, collectively referred to as next generation sequencing (NGS), mean the entire cancer genome or parts of it can now be sequenced at speed with increased depth and sensitivity. However, translation of NGS into routine cancer care has been slow. Healthcare stakeholders are unclear about the clinical utility of NGS and are concerned it could be an expensive addition to cancer diagnostics, rather than an affordable alternative to single gene testing.Methods and Findings: We validated a 46-gene hotspot cancer panel assay allowing multiple gene testing from small diagnostic biopsies. From 1 January 2013 to 31 December 2013, solid tumour samples (including non-small-cell lung carcinoma [NSCLC], colorectal carcinoma, and melanoma) were sequenced in the context of the UK National Health Service from 351 consecutively submitted prospective cases for which treating clinicians thought the patient had potential to benefit from more extensive genetic analysis. Following histological assessment, tumour-rich regions of formalin-fixed paraffin-embedded (FFPE) sections underwent macrodissection, DNA extraction, NGS, and analysis using a pipeline centred on Torrent Suite software. With a median turnaround time of seven working days, an integrated clinical report was produced indicating the variants detected, including those with potential diagnostic, prognostic, therapeutic, or clinical trial entry implications. Accompanying phenotypic data were collected, and a detailed cost analysis of the panel compared with single gene testing was undertaken to assess affordability for routine patient care. Panel sequencing was successful for 97% (342/351) of tumour samples in the prospective cohort and showed 100% concordance with known mutations (detected using cobas assays). At least one mutation was identified in 87% (296/342) of tumours. A locally actionable mutation (i.e., available targeted treatment or clinical trial) was identified in 122/351 patients (35%). Forty patients received targeted treatment, in 22/40 (55%) cases solely due to use of the panel. Examination of published data on the potential efficacy of targeted therapies showed theoretically actionable mutations (i.e., mutations for which targeted treatment was potentially appropriate) in 66% (71/107) and 39% (41/105) of melanoma and NSCLC patients, respectively. At a cost of £339 (US$449) per patient, the panel was less expensive locally than performing more than two or three single gene tests. Study limitations include the use of FFPE samples, which do not always provide high-quality DNA, and the use of "real world" data: submission of cases for sequencing did not always follow clinical guidelines, meaning that when mutations were detected, patients were not always eligible for targeted treatments on clinical grounds.Conclusions: This study demonstrates that more extensive tumour sequencing can identify mutations that could improve clinical decision-making in routine cancer care, potentially improving patient outcomes, at an affordable level for healthcare providers. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
- Author
-
ten Haaf, Kevin, Tammemägi, Martin C., Bondy, Susan J., van der Aalst, Carlijn M., Gu, Sumei, McGregor, S. Elizabeth, Nicholas, Garth, de Koning, Harry J., and Paszat, Lawrence F.
- Subjects
CANCER tomography ,LUNG cancer ,COST effectiveness ,MICROSIMULATION modeling (Statistics) ,OVERTREATMENT of cancer ,SMOKING ,LUNG tumors ,MEDICAL screening ,EARLY detection of cancer ,COMPUTED tomography ,DIAGNOSTIC errors ,MATHEMATICAL models ,MORTALITY ,RESEARCH funding ,THEORY ,DIAGNOSIS ,ECONOMICS - Abstract
Background: The National Lung Screening Trial (NLST) results indicate that computed tomography (CT) lung cancer screening for current and former smokers with three annual screens can be cost-effective in a trial setting. However, the cost-effectiveness in a population-based setting with >3 screening rounds is uncertain. Therefore, the objective of this study was to estimate the cost-effectiveness of lung cancer screening in a population-based setting in Ontario, Canada, and evaluate the effects of screening eligibility criteria.Methods and Findings: This study used microsimulation modeling informed by various data sources, including the Ontario Health Insurance Plan (OHIP), Ontario Cancer Registry, smoking behavior surveys, and the NLST. Persons, born between 1940 and 1969, were examined from a third-party health care payer perspective across a lifetime horizon. Starting in 2015, 576 CT screening scenarios were examined, varying by age to start and end screening, smoking eligibility criteria, and screening interval. Among the examined outcome measures were lung cancer deaths averted, life-years gained, percentage ever screened, costs (in 2015 Canadian dollars), and overdiagnosis. The results of the base-case analysis indicated that annual screening was more cost-effective than biennial screening. Scenarios with eligibility criteria that required as few as 20 pack-years were dominated by scenarios that required higher numbers of accumulated pack-years. In general, scenarios that applied stringent smoking eligibility criteria (i.e., requiring higher levels of accumulated smoking exposure) were more cost-effective than scenarios with less stringent smoking eligibility criteria, with modest differences in life-years gained. Annual screening between ages 55-75 for persons who smoked ≥40 pack-years and who currently smoke or quit ≤10 y ago yielded an incremental cost-effectiveness ratio of $41,136 Canadian dollars ($33,825 in May 1, 2015, United States dollars) per life-year gained (compared to annual screening between ages 60-75 for persons who smoked ≥40 pack-years and who currently smoke or quit ≤10 y ago), which was considered optimal at a cost-effectiveness threshold of $50,000 Canadian dollars ($41,114 May 1, 2015, US dollars). If 50% lower or higher attributable costs were assumed, the incremental cost-effectiveness ratio of this scenario was estimated to be $38,240 ($31,444 May 1, 2015, US dollars) or $48,525 ($39,901 May 1, 2015, US dollars), respectively. If 50% lower or higher costs for CT examinations were assumed, the incremental cost-effectiveness ratio of this scenario was estimated to be $28,630 ($23,542 May 1, 2015, US dollars) or $73,507 ($60,443 May 1, 2015, US dollars), respectively. This scenario would screen 9.56% (499,261 individuals) of the total population (ever- and never-smokers) at least once, which would require 4,788,523 CT examinations, and reduce lung cancer mortality in the total population by 9.05% (preventing 13,108 lung cancer deaths), while 12.53% of screen-detected cancers would be overdiagnosed (4,282 overdiagnosed cases). Sensitivity analyses indicated that the overall results were most sensitive to variations in CT examination costs. Quality of life was not incorporated in the analyses, and assumptions for follow-up procedures were based on data from the NLST, which may not be generalizable to a population-based setting.Conclusions: Lung cancer screening with stringent smoking eligibility criteria can be cost-effective in a population-based setting. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
12. Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians' Practices across Six Randomised Controlled Trials.
- Author
-
Rooshenas, Leila, Elliott, Daisy, Wade, Julia, Jepson, Marcus, Paramasivan, Sangeetha, Strong, Sean, Wilson, Caroline, Beard, David, Blazeby, Jane M., Birtle, Alison, Halliday, Alison, Rogers, Chris A., Stein, Rob, Donovan, Jenny L., null, null, ACST-2 study group, By-Band-Sleeve study group, Chemorad study group, CSAW study group, and Optima prelim study group
- Subjects
MEDICAL personnel ,CLINICAL pharmacology ,MEDICAL research ,RANDOMIZED controlled trials ,CLINICAL trials ,ATTITUDE (Psychology) ,CLINICAL competence ,COMMUNICATION ,HEALTH attitudes ,PHYSICIAN-patient relations ,PATIENT selection - Abstract
Background: Randomised controlled trials (RCTs) are essential for evidence-based medicine and increasingly rely on front-line clinicians to recruit eligible patients. Clinicians' difficulties with negotiating equipoise is assumed to undermine recruitment, although these issues have not yet been empirically investigated in the context of observable events. We aimed to investigate how clinicians conveyed equipoise during RCT recruitment appointments across six RCTs, with a view to (i) identifying practices that supported or hindered equipoise communication and (ii) exploring how clinicians' reported intentions compared with their actual practices.Methods and Findings: Six pragmatic UK-based RCTs were purposefully selected to include several clinical specialties (e.g., oncology, surgery) and types of treatment comparison. The RCTs were all based in secondary-care hospitals (n = 16) around the UK. Clinicians recruiting to the RCTs were interviewed (n = 23) to understand their individual sense of equipoise about the RCT treatments and their intentions for communicating equipoise to patients. Appointments in which these clinicians presented the RCT to trial-eligible patients were audio-recorded (n = 105). The appointments were analysed using thematic and content analysis approaches to identify practices that supported or challenged equipoise communication. A sample of appointments was independently coded by three researchers to optimise reliability in reported findings. Clinicians and patients provided full written consent to be interviewed and have appointments audio-recorded. Interviews revealed that clinicians' sense of equipoise varied: although all were uncertain about which trial treatment was optimal, they expressed different levels of uncertainty, ranging from complete ambivalence to clear beliefs that one treatment was superior. Irrespective of their personal views, all clinicians intended to set their personal biases aside to convey trial treatments neutrally to patients (in accordance with existing evidence). However, equipoise was omitted or compromised in 48/105 (46%) of the recorded appointments. Three commonly recurring practices compromised equipoise communication across the RCTs, irrespective of clinical context. First, equipoise was overridden by clinicians offering treatment recommendations when patients appeared unsure how to proceed or when they asked for the clinician's expert advice. Second, clinicians contradicted equipoise by presenting imbalanced descriptions of trial treatments that conflicted with scientific information stated in the RCT protocols. Third, equipoise was undermined by clinicians disclosing their personal opinions or predictions about trial outcomes, based on their intuition and experience. These broad practices were particularly demonstrated by clinicians who had indicated in interviews that they held less balanced views about trial treatments. A limitation of the study was that clinicians volunteering to take part in the research might have had a particular interest in improving their communication skills. However, the frequency of occurrence of equipoise issues across the RCTs suggests that the findings are likely to be reflective of clinical recruiters' practices more widely.Conclusions: Communicating equipoise is a challenging process that is easily disrupted. Clinicians' personal views about trial treatments encroached on their ability to convey equipoise to patients. Clinicians should be encouraged to reflect on personal biases and be mindful of the common ways in which these can arise in their discussions with patients. Common pitfalls that recurred irrespective of RCT context indicate opportunities for specific training in communication skills that would be broadly applicable to a wide clinical audience. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
13. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
- Author
-
Leung, William, Kvizhinadze, Giorgi, Nair, Nisha, and Blakely, Tony
- Subjects
TRASTUZUMAB ,BREAST cancer treatment ,HER2 protein ,BREAST cancer patients ,HORMONE receptor positive breast cancer ,COST effectiveness ,HEALTH ,COMBINED modality therapy ,AGE distribution ,BREAST tumors ,CELL receptors ,GENES ,MEDICAL care costs ,PROBABILITY theory ,PROTEINS ,QUALITY of life ,ECONOMICS - Abstract
Background: The anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab improves outcomes in patients with node-positive HER2+ early breast cancer. Given trastuzumab's high cost, we aimed to estimate its cost-effectiveness by heterogeneity in age and estrogen receptor (ER) and progesterone receptor (PR) status, which has previously been unexplored, to assist prioritisation.Methods and Findings: A cost-utility analysis was performed using a Markov macro-simulation model, with a lifetime horizon, comparing a 12-mo regimen of trastuzumab with chemotherapy alone using the latest (2014) effectiveness measures from landmark randomised trials. A New Zealand (NZ) health system perspective was adopted, employing high-quality national administrative data. Incremental quality-adjusted life-years for trastuzumab versus chemotherapy alone are two times higher (2.33 times for the age group 50-54 y; 95% CI 2.29-2.37) for the worst prognosis (ER-/PR-) subtype compared to the best prognosis (ER+/PR+) subtype, causing incremental cost-effectiveness ratios (ICERs) for the former to be less than half those of the latter for the age groups from 25-29 to 90-94 y (0.44 times for the age group 50-54 y; 95% CI 0.43-0.45). If we were to strictly apply an arbitrary cost-effectiveness threshold equal to the NZ gross domestic product per capita (2011 purchasing power parity [PPP]-adjusted: US$30,300; €23,700; £21,200), our study suggests that trastuzumab (2011 PPP-adjusted US$45,400/€35,900/£21,900 for 1 y at formulary prices) may not be cost-effective for ER+ (which are 61% of all) node-positive HER2+ early breast cancer patients but cost-effective for ER-/PR- subtypes (37% of all cases) to age 69 y. Market entry of trastuzumab biosimilars will likely reduce the ICER to below this threshold for premenopausal ER+/PR- cancer but not for ER+/PR+ cancer. Sensitivity analysis using the best-case effectiveness measure for ER+ cancer had the same result. A key limitation was a lack of treatment-effect data by hormone receptor subtype. Heterogeneity was restricted to age and hormone receptor status; tumour size/grade heterogeneity could be explored in future work.Conclusions: This study highlights how cost-effectiveness can vary greatly by heterogeneity in age and hormone receptor subtype. Resource allocation and licensing of subsidised therapies such as trastuzumab should consider demographic and clinical heterogeneity; there is currently a profound disconnect between how funding decisions are made (largely agnostic to heterogeneity) and the principles of personalised medicine. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
14. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
- Author
-
Gnanapragasam, Vincent J., Lophatananon, Artitaya, Wright, Karen A., Muir, Kenneth R., Gavin, Anna, and Greenberg, David C.
- Subjects
DIAGNOSIS ,PROSTATE cancer ,HEALTH risk assessment ,DECISION making in clinical medicine ,PROSTATE cancer risk factors ,GLEASON grading system - Abstract
Introduction: Over 80% of the nearly 1 million men diagnosed with prostate cancer annually worldwide present with localised or locally advanced non-metastatic disease. Risk stratification is the cornerstone for clinical decision making and treatment selection for these men. The most widely applied stratification systems use presenting prostate-specific antigen (PSA) concentration, biopsy Gleason grade, and clinical stage to classify patients as low, intermediate, or high risk. There is, however, significant heterogeneity in outcomes within these standard groupings. The International Society of Urological Pathology (ISUP) has recently adopted a prognosis-based pathological classification that has yet to be included within a risk stratification system. Here we developed and tested a new stratification system based on the number of individual risk factors and incorporating the new ISUP prognostic score.Methods and Findings: Diagnostic clinicopathological data from 10,139 men with non-metastatic prostate cancer were available for this study from the Public Health England National Cancer Registration Service Eastern Office. This cohort was divided into a training set (n = 6,026; 1,557 total deaths, with 462 from prostate cancer) and a testing set (n = 4,113; 1,053 total deaths, with 327 from prostate cancer). The median follow-up was 6.9 y, and the primary outcome measure was prostate-cancer-specific mortality (PCSM). An external validation cohort (n = 1,706) was also used. Patients were first categorised as low, intermediate, or high risk using the current three-stratum stratification system endorsed by the National Institute for Health and Care Excellence (NICE) guidelines. The variables used to define the groups (PSA concentration, Gleason grading, and clinical stage) were then used to sub-stratify within each risk category by testing the individual and then combined number of risk factors. In addition, we incorporated the new ISUP prognostic score as a discriminator. Using this approach, a new five-stratum risk stratification system was produced, and its prognostic power was compared against the current system, with PCSM as the outcome. The results were analysed using a Cox hazards model, the log-rank test, Kaplan-Meier curves, competing-risks regression, and concordance indices. In the training set, the new risk stratification system identified distinct subgroups with different risks of PCSM in pair-wise comparison (p < 0.0001). Specifically, the new classification identified a very low-risk group (Group 1), a subgroup of intermediate-risk cancers with a low PCSM risk (Group 2, hazard ratio [HR] 1.62 [95% CI 0.96-2.75]), and a subgroup of intermediate-risk cancers with an increased PCSM risk (Group 3, HR 3.35 [95% CI 2.04-5.49]) (p < 0.0001). High-risk cancers were also sub-classified by the new system into subgroups with lower and higher PCSM risk: Group 4 (HR 5.03 [95% CI 3.25-7.80]) and Group 5 (HR 17.28 [95% CI 11.2-26.67]) (p < 0.0001), respectively. These results were recapitulated in the testing set and remained robust after inclusion of competing risks. In comparison to the current risk stratification system, the new system demonstrated improved prognostic performance, with a concordance index of 0.75 (95% CI 0.72-0.77) versus 0.69 (95% CI 0.66-0.71) (p < 0.0001). In an external cohort, the new system achieved a concordance index of 0.79 (95% CI 0.75-0.84) for predicting PCSM versus 0.66 (95% CI 0.63-0.69) (p < 0.0001) for the current NICE risk stratification system. The main limitations of the study were that it was registry based and that follow-up was relatively short.Conclusions: A novel and simple five-stratum risk stratification system outperforms the standard three-stratum risk stratification system in predicting the risk of PCSM at diagnosis in men with primary non-metastatic prostate cancer, even when accounting for competing risks. This model also allows delineation of new clinically relevant subgroups of men who might potentially receive more appropriate therapy for their disease. Future research will seek to validate our results in external datasets and will explore the value of including additional variables in the system in order in improve prognostic performance. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
15. On Risk Estimation versus Risk Stratification in Early Prostate Cancer.
- Author
-
Carlsson, Sigrid V. and Kattan, Michael W.
- Subjects
PROSTATE cancer risk factors ,HEALTH risk assessment ,PROSTATECTOMY ,CANCER radiotherapy ,RANDOMIZED controlled trials ,BIOMARKERS ,WATCHFUL waiting ,PROSTATE tumors treatment ,PROGNOSIS ,PROSTATE ,PROSTATE tumors ,RISK assessment ,DIAGNOSIS - Abstract
In a Perspective article, Sigrid Carlsson and Michael Kattan discuss Gnanapragasam and colleagues' accompanying research study on refining risk stratification in early prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma.
- Author
-
Farinati, Fabio, Vitale, Alessandro, Spolverato, Gaya, Pawlik, Timothy M., Huo, Teh-la, Lee, Yun-Hsuan, Frigo, Anna Chiara, Giacomin, Anna, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, and Morisco, Filomena
- Subjects
PROGNOSTIC tests ,LIVER cancer ,TUMOR classification ,ALPHA fetoproteins ,ANTHROPOMETRY ,CANCER invasiveness ,COMPARATIVE studies ,DATABASES ,DECISION making ,HEPATOCELLULAR carcinoma ,LIVER tumors ,RESEARCH methodology ,MEDICAL cooperation ,MULTIPLE tumors ,RESEARCH ,RESEARCH evaluation ,RISK assessment ,SURVIVAL analysis (Biometry) ,TIME ,EVALUATION research ,PREDICTIVE tests ,RETROSPECTIVE studies - Abstract
Background: Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC.Methods and Findings: Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metastases). A parametric multivariable survival model was then used to calculate the relative prognostic value of ITA.LI.CA tumor stage, Eastern Cooperative Oncology Group (ECOG) performance status, Child-Pugh score (CPS), and alpha-fetoprotein (AFP) in predicting individual survival. Based on the model results, an ITA.LI.CA integrated prognostic score (from 0 to 13 points) was constructed, and its prognostic power compared with that of other integrated systems (BCLC, HKLC, MESIAH, CLIP, JIS). Median follow-up was 58 mo for Italian patients (interquartile range, 26-106 mo) and 39 mo for Taiwanese patients (interquartile range, 12-61 mo). The ITA.LI.CA integrated prognostic score showed optimal discrimination and calibration abilities in Italian patients. Observed median survival in the training and internal validation sets was 57 and 61 mo, respectively, in quartile 1 (ITA.LI.CA score ≤ 1), 43 and 38 mo in quartile 2 (ITA.LI.CA score 2-3), 23 and 23 mo in quartile 3 (ITA.LI.CA score 4-5), and 9 and 8 mo in quartile 4 (ITA.LI.CA score > 5). Observed and predicted median survival in the training and internal validation sets largely coincided. Although observed and predicted survival estimations were significantly lower (log-rank test, p < 0.001) in Italian than in Taiwanese patients, the ITA.LI.CA score maintained very high discrimination and calibration features also in the external validation cohort. The concordance index (C index) of the ITA.LI.CA score in the internal and external validation cohorts was 0.71 and 0.78, respectively. The ITA.LI.CA score's prognostic ability was significantly better (p < 0.001) than that of BCLC stage (respective C indexes of 0.64 and 0.73), CLIP score (0.68 and 0.75), JIS stage (0.67 and 0.70), MESIAH score (0.69 and 0.77), and HKLC stage (0.68 and 0.75). The main limitations of this study are its retrospective nature and the intrinsically significant differences between the Taiwanese and Italian groups.Conclusions: The ITA.LI.CA prognostic system includes both a tumor staging-stratifying patients with HCC into six main stages (0, A, B1, B2, B3, and C)-and a prognostic score-integrating ITA.LI.CA tumor staging, CPS, ECOG performance status, and AFP. The ITA.LI.CA prognostic system shows a strong ability to predict individual survival in European and Asian populations. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
17. Open Access to Large Scale Datasets Is Needed to Translate Knowledge of Cancer Heterogeneity into Better Patient Outcomes.
- Author
-
Beck, Andrew H.
- Subjects
BIG data ,CANCER treatment ,CANCER genetics ,CANCER patients ,CANCER research - Abstract
In this guest editorial, Andrew Beck discusses the importance of open access to big data for translating knowledge of cancer heterogeneity into better outcomes for cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration.
- Author
-
Altman, Douglas G., McShane, Lisa M., Sauerbrei, Willi, and Taube, Sheila E.
- Subjects
TUMOR markers ,CANCER treatment ,PROGNOSIS - Abstract
The article presents a study which provides detailed explanations on the checklist items in the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). It is inferred that the recommendations were developed by the European Organization for Research and Treatment of Cancer and the National Cancer Institute. An overview on the proper method of reporting prognostic marker research is provided.
- Published
- 2012
- Full Text
- View/download PDF
19. Complexity in Non-Pharmacological Caregiving Activities at the End of Life: An International Qualitative Study.
- Author
-
Lindqvist, Olav, Tishelman, Carol, Hagelin, Carina Lundh, Clark, Jean B., Daud, Maria L., Dickman, Andrew, Benedetti, Franzisca Domeisen, Galushko, Maren, Lunder, Urska, Lundquist, Gunilla, Miccinesi, Guido, Sauter, Sylvia B., Fürst, Carl Johan, and Rasmussen, Birgit H.
- Subjects
CANCER patients ,CANCER treatment ,HOSPICE care ,PALLIATIVE treatment ,TERMINAL care - Abstract
Background: In late-stage palliative cancer care, relief of distress and optimized well-being become primary treatment goals. Great strides have been made in improving and researching pharmacological treatments for symptom relief; however, little systematic knowledge exists about the range of non-pharmacological caregiving activities (NPCAs) staff use in the last days of a patient's life. Methods and Findings: Within a European Commission Seventh Framework Programme project to optimize research and clinical care in the last days of life for patients with cancer, OPCARE9, we used a free-listing technique to identify the variety of NPCAs performed in the last days of life. Palliative care staff at 16 units in nine countries listed in detail NPCAs they performed over several weeks. In total, 914 statements were analyzed in relation to (a) the character of the statement and (b) the recipient of the NPCA. A substantial portion of NPCAs addressed bodily care and contact with patients and family members, with refraining from bodily care also described as a purposeful caregiving activity. Several forms for communication were described; information and advice was at one end of a continuum, and communicating through nonverbal presence and bodily contact at the other. Rituals surrounding death and dying included not only spiritual/ religious issues, but also more subtle existential, legal, and professional rituals. An unexpected and hitherto underresearched area of focus was on creating an aesthetic, safe, and pleasing environment, both at home and in institutional care settings. Conclusions: Based on these data, we argue that palliative care in the last days of life is multifaceted, with physical, psychological, social, spiritual, and existential care interwoven in caregiving activities. Providing for fundamental human needs close to death appears complex and sophisticated; it is necessary to better distinguish nuances in such caregiving to acknowledge, respect, and further develop end-of-life care. [ABSTRACT FROM AUTHOR]
- Published
- 2012
20. Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma.
- Author
-
Lockwood, William W., Chari, Raj, Coe, Bradley P., Thu, Kelsie L., Garnis, Cathie, Malloff, Chad A., Campbell, Jennifer, Williams, Ariane C., Hwang, Dorothy, Chang-Qi Zhu, Buys, Timon P. H., Yee, John, English, John C., MacAulay, Calum, Tsao, Ming-Sound, Gazdar, Adi F., Minna, John D., Lam, Stephen, and Lam, Wan L.
- Subjects
LUNG cancer & genetics ,SQUAMOUS cell carcinoma ,CANCER treatment ,ONCOGENES ,GENOMIC imprinting ,TUMOR growth ,TRANSCRIPTION factors ,BIOMARKERS ,RNA - Abstract
Background: Traditionally, non-small cell lung cancer is treated as a single disease entity in terms of systemic therapy. Emerging evidence suggests the major subtypes—adenocarcinoma (AC) and squamous cell carcinoma (SqCC)—respond differently to therapy. Identification of the molecular differences between these tumor types will have a significant impact in designing novel therapies that can improve the treatment outcome. Methods and Findings: We used an integrative genomics approach, combing high-resolution comparative genomic hybridization and gene expression microarray profiles, to compare AC and SqCC tumors in order to uncover alterations at the DNA level, with corresponding gene transcription changes, which are selected for during development of lung cancer subtypes. Through the analysis of multiple independent cohorts of clinical tumor samples (.330), normal lung tissues and bronchial epithelial cells obtained by bronchial brushing in smokers without lung cancer, we identified the overexpression of BRF2, a gene on Chromosome 8p12, which is specific for development of SqCC of lung. Genetic activation of BRF2, which encodes a RNA polymerase III (Pol III) transcription initiation factor, was found to be associated with increased expression of small nuclear RNAs (snRNAs) that are involved in processes essential for cell growth, such as RNA splicing. Ectopic expression of BRF2 in human bronchial epithelial cells induced a transformed phenotype and demonstrates downstream oncogenic effects, whereas RNA interference (RNAi)-mediated knockdown suppressed growth and colony formation of SqCC cells overexpressing BRF2, but not AC cells. Frequent activation of BRF2 in .35% preinvasive bronchial carcinoma in situ, as well as in dysplastic lesions, provides evidence that BRF2 expression is an early event in cancer development of this cell lineage. Conclusions: This is the first study, to our knowledge, to show that the focal amplification of a gene in Chromosome 8p12, plays a key role in squamous cell lineage specificity of the disease. Our data suggest that genetic activation of BRF2 represents a unique mechanism of SqCC lung tumorigenesis through the increase of Pol III-mediated transcription. It can serve as a marker for lung SqCC and may provide a novel target for therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
21. The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway.
- Author
-
Gordon, Ira, Paoloni, Melissa, Mazcko, Christina, and Khanna, Chand
- Subjects
CLINICAL trials ,CANCER treatment ,ONCOLOGY ,CLINICAL medicine research ,INFORMATION services ,MEDICAL experimentation on humans ,MANAGEMENT - Abstract
The article offers information about the Comparative Oncology Trials Consortium (COTC) of the National Cancer Institute (NCI) in the U.S. It notes that COTC offers infrastructure and resources which are necessary in integrating cancer models into the development of cancer drugs, imaging techniques and devices. It is designed to execute clinical trials in dogs suffering from cancer. It also develops an electronic reporting system for data collection and provide study result monitoring.
- Published
- 2009
- Full Text
- View/download PDF
22. The Quest for a Vaccine That Yields Tumor-Killing T cells.
- Author
-
Stuge, T. B., Holmes, S. P., and Tuettenberg, A.
- Subjects
CANCER vaccines ,IMMUNE system ,T cells ,PEPTIDES ,CANCER treatment - Abstract
Presents the results of a study on the development of a vaccine for tumor-killing T cells. Role of the immune system in the prevention of cancer; Background on the use of immune therapy in the treatment of malignant melanoma; Effect of heteroclitic peptides on T cell responses.
- Published
- 2004
- Full Text
- View/download PDF
23. Should Informed Consent for Cancer Treatment Include a Discussion about Hospital Outcome Disparities?
- Author
-
Housri, Nadine, Weil, Robert J., Shalowitz, David I., and Koniaris, Leonidas G.
- Subjects
DEBATE ,MEDICAL ethics ,INFORMED consent (Medical law) ,PHYSICIAN-patient relations ,CANCER treatment - Abstract
The article reports on the debate which probes whether physicians have ethical obligations to inform patients of hospital outcome for cancer. Physicians Nadine Housri and Leonidas Koniaris argue that physicians have ethical duties to communicate with patients to maintain trust and honesty in the physician-patient relationship. Biomedical expert David Shalowitz believes that more work must be done to elucidate patients' desire for outcome data before it will be used in clinical decision-making.
- Published
- 2008
- Full Text
- View/download PDF
24. Optimal Management of High-Risk T1G3 Bladder Cancer: A Decision Analysis.
- Author
-
Kulkarni, Girish S., Finelli, Antonio, Fleshner, Neil E., Jewett, Michael A. S., Lopushinsky, Steven R., and Alibhai, Shabbir M. H.
- Subjects
BLADDER cancer ,CANCER treatment ,CANCER patients ,COMORBIDITY ,DECISION making - Abstract
Using a Markov model, Shabbir Alibhai and colleagues develop a decision analysis comparing cystectomy with conservative treatment for high-risk superficial bladder cancer depending on patient age, comorbid conditions, and preferences. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
25. Analysis of Gene Expression Using Gene Sets Discriminates Cancer Patients with and without Late Radiation Toxicity.
- Author
-
Svensson, J. Peter, Stalpers, Lukas J. A., Esveldt, van Lange, Rebecca E. E., Franken, Nicolaas A. P., Haveman, Jaap, Klein, Binie, Turesson, Ingela, Vrieling, Harry, and Giphart-Gassler, Micheline
- Subjects
GENE expression ,CANCER patients ,CANCER treatment ,X-rays ,RADIOGRAPHY - Abstract
Background Radiation is an effective anti-cancer therapy but leads to severe late radiation toxicity in 5%- 10% of patients. Assuming that genetic susceptibility impacts this risk, we hypothesized that the cellular response of normal tissue to X-rays could discriminate patients with and without late radiation toxicity. Methods and Findings Prostate carcinoma patients without evidence of cancer 2 y after curative radiotherapy were recruited in the study. Blood samples of 21 patients with severe late complications from radiation and 17 patients without symptoms were collected. Stimulated peripheral lymphocytes were mock-irradiated or irradiated with 2-Gy X-rays. The 24-h radiation response was analyzed by gene expression profiling and used for classification. Classification was performed either on the expression of separate genes or, to augment the classification power, on gene sets consisting of genes grouped together based on function or cellular colocalization. X-ray irradiation altered the expression of radio-responsive genes in both groups. This response was variable across individuals, and the expression of the most significant radioresponsive genes was unlinked to radiation toxicity. The classifier based on the radiation response of separate genes correctly classified 63% of the patients. The classifier based on affected gene sets improved correct classification to 86%, although on the individual level only 21/38 (55%) patients were classified with high certainty. The majority of the discriminative genes and gene sets belonged to the ubiquitin, apoptosis, and stress signaling networks. The apoptotic response appeared more pronounced in patients that did not develop toxicity. In an independent set of 12 patients, the toxicity status of eight was predicted correctly by the gene set classifier. Conclusions Gene expression profiling succeeded to some extent in discriminating groups of patients with and without severe late radiotherapy toxicity. Moreover, the discriminative power was enhanced by assessment of functionally or structurally related gene sets. While prediction of individual response requires improvement, this study is a step forward in predicting susceptibility to late radiation toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
26. New Approach to Combat Glioblastoma Shows Promise in Preclinical Studies.
- Subjects
GLIOBLASTOMA multiforme ,CANCER treatment ,MEDICAL research ,GENE therapy ,EPIDERMAL growth factor - Abstract
The article presents information on a study by A. Shir, M. Ogris, E. Wagner and A. Levitzki on the treatment of Glioblastoma multiforme (GBM). According to the article, researchers are studying several methods to treat GBM using gene therapy. The researchers examined the frequent overexpression of the epidermal growth factor receptors in GBM.
- Published
- 2006
- Full Text
- View/download PDF
27. Diversity and Recognition Efficiency of T Cell Responses to Cancer.
- Author
-
Stuge, Tor B., Holmes, Susan P., Saharan, Sahdev, Tuettenberg, Andrea, Roederer, Mario, Weber, Jeffrey S., and Lee, Peter P.
- Subjects
CANCER treatment ,T cells ,ANTIGENS ,IMMUNOTHERAPY ,TUMORS - Abstract
Melanoma patients vaccinated with tumor-associated antigens frequently develop measurable peptide-specific CD8 + T cell responses; however, such responses often do not confer clinical benefit. Understanding why vaccine-elicited responses are beneficial in some patients but not in others will be important to improve targeted cancer immunotherapies. Methods and Findings We analyzed peptide-specific CD8 + T cell responses in detail, by generating and characterizing over 200 cytotoxic T lymphocyte clones derived from T cell responses to heteroclitic peptide vaccination, and compared these responses to endogenous anti-tumor T cell responses elicited naturally (a heteroclitic peptide is a modification of a native peptide sequence involving substitution of an amino acid at an anchor residue to enhance the immunogenicity of the peptide). We found that vaccine-elicited T cells are diverse in T cell receptor variable chain beta expression and exhibit a different recognition profile for heteroclitic versus native peptide. In particular, vaccine-elicited T cells respond to native peptide with predominantly low recognition efficiency--a measure of the sensitivity of a T cell to different cognate peptide concentrations for stimulation--and, as a result, are inefficient in tumor lysis. In contrast, endogenous tumor-associated-antigen-specific T cells show a predominantly high recognition efficiency for native peptide and efficiently lyse tumor targets. Conclusions These results suggest that factors that shape the peptide-specific T cell repertoire after vaccination may be different from those that affect the endogenous response. Furthermore, our findings suggest that current heteroclitic peptide vaccination protocols drive expansion of peptide-specific T cells with a diverse range of recognition efficiencies, a significant proportion of which are unable to respond to melanoma cells. Therefore, it is critical that the recognition efficiency of vaccine-elicited T cells be... [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
28. How Tumor Cells Acquire Resistance to Kinase Inhibitors.
- Subjects
DRUG resistance in cancer cells ,CANCER cells ,EPIDERMAL growth factor ,SMALL cell lung cancer ,CANCER treatment - Abstract
Discusses how tumor cells acquire resistance to kinase inhibitors. Importance of understanding the mechanisms in which tumors become resistant to a particular agent; Information on kinases and epidermal growth factor receptor; Results of a study by William Pao and colleagues on patients with non-small cell lung cancer who initially responded to getifinib and erlotinib treatment.
- Published
- 2005
- Full Text
- View/download PDF
29. Targeted Nanoparticles for Imaging Incipient Pancreatic Ductal Adenocarcinoma.
- Author
-
Anbazhagan, Rajesh, Gurumurthy, Sushma, Berger, Justin, Alencar, Herlen, DePinho, Ronald A., Mahmood, Umar, and Weissleder, Ralph
- Subjects
ADENOCARCINOMA ,CANCER treatment ,NANOPARTICLES ,PANCREATIC duct ,PANCREATIC tumors ,BIOMARKERS ,BIOCHEMISTRY ,CANCER ,THERAPEUTICS - Abstract
Kimberly Kelly and colleagues describe the discovery of plectin-1 as a novel biomarker for pancreatic ductal adenocarcinoma and the subsequent development of a specific imaging probe using this marker. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
30. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study
- Author
-
Kaboré, Elisé G., Guenancia, Charles, Vaz-Luis, Ines, Di Meglio, Antonio, Pistilli, Barbara, Coutant, Charles, Cottu, Paul, Lesur, Anne, Petit, Thierry, Dalenc, Florence, Rouanet, Philippe, Arnaud, Antoine, Arsene, Olivier, Ibrahim, Mahmoud, Wassermann, Johanna, Boileau-Jolimoy, Geneviève, Martin, Anne-Laure, Lemonnier, Jérôme, André, Fabrice, and Arveux, Patrick
- Subjects
Obesity -- Care and treatment -- Risk factors -- Analysis ,Anthracyclines -- Analysis ,Monoclonal antibodies -- Analysis ,Cancer research -- Analysis ,Chemotherapy -- Analysis ,Body mass index -- Analysis ,Breast cancer -- Care and treatment -- Risk factors -- Analysis ,Cardiovascular diseases -- Care and treatment -- Risk factors -- Analysis ,Antibiotics ,Cancer treatment ,Toxicity ,Antineoplastic agents ,Medical research ,Antibodies ,Biological sciences - Abstract
Background In patients treated with cardiotoxic chemotherapies, the presence of cardiovascular risk factors and previous cardiac disease have been strongly correlated to the onset of cardiotoxicity. The influence of overweight and obesity as risk factors in the development of treatment-related cardiotoxicity in breast cancer (BC) was recently suggested. However, due to meta-analysis design, it was not possible to take into account associated cardiac risk factors or other classic risk factors for anthracycline (antineoplastic antibiotic) and trastuzumab (monoclonal antibody) cardiotoxicity. Methods and findings Using prospective data collected from 2012-2014 in the French national multicenter prospective CANTO (CANcer TOxicities) study of 26 French cancer centers, we aimed to examine the association of body mass index (BMI) and cardiotoxicity (defined as a reduction in left ventricular ejection fraction [LVEF] > 10 percentage points from baseline to LVEF < 50%). In total, 929 patients with stage I-III BC (mean age 52 ± 11 years, mean BMI 25.6 ± 5.1 kg/m.sup.2, 42% with 1 or more cardiovascular risk factors) treated with anthracycline (86% epirubicin, 7% doxorubicin) and/or trastuzumab (36%), with LVEF measurement at baseline and at least 1 assessment post-chemotherapy were eligible in this interim analysis. We analyzed associations between BMI and cardiotoxicity using multivariate logistic regression. At baseline, nearly 50% of the study population was overweight or obese. During a mean follow-up of 22 ± 2 months following treatment completion, cardiotoxicity occurred in 29 patients (3.2%). The obese group was more prone to cardiotoxicity than the normal-weight group (9/171 versus 8/466; p = 0.01). In multivariate analysis, obesity (odds ratio [OR] 3.02; 95% CI 1.10-8.25; p = 0.03) and administration of trastuzumab (OR 12.12; 95% CI 3.6-40.4; p < 0.001) were independently associated with cardiotoxicity. Selection bias and relatively short follow-up are potential limitations of this national multicenter observational cohort. Conclusions In BC patients, obesity appears to be associated with an important increase in risk-related cardiotoxicity (CANTO, ClinicalTrials.gov registry ID: NCT01993498). Trial registration ClinicalTrials.gov NCT01993498., Author(s): Elisé G. Kaboré 1, Charles Guenancia 2,*, Ines Vaz-Luis 3, Antonio Di Meglio 3, Barbara Pistilli 3, Charles Coutant 4, Paul Cottu 5, Anne Lesur 6, Thierry Petit 7, [...]
- Published
- 2019
- Full Text
- View/download PDF
31. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial
- Author
-
Walsh, Jennifer S. and Marshall, Helen
- Subjects
EPUB (Standard) ,Clinical trials ,Cancer survivors ,Testosterone -- Research ,Cancer research ,Chemotherapy ,Leukemia -- Research ,Lymphomas -- Research ,Cancer treatment ,Radiotherapy ,Testicular cancer ,Cancer ,Tumors ,Biological sciences - Abstract
Background Young male cancer survivors have lower testosterone levels, higher fat mass, and worse quality of life (QoL) than age-matched healthy controls. Low testosterone in cancer survivors can be due to orchidectomy or effects of chemotherapy and radiotherapy. We have undertaken a double-blind, placebo-controlled, 6-month trial of testosterone replacement in young male cancer survivors with borderline low testosterone (7-12 nmol/l). Methods and findings This was a multicentre United Kingdom study conducted in secondary care hospital outpatients. Male survivors of testicular cancer, lymphoma, and leukaemia aged 25-50 years with morning total serum testosterone 7-12 nmol/l were recruited. A total of 136 men were randomised between July 2012 and February 2015 (42.6% aged 25-37 years, 57.4% 38-50 years, 88% testicular cancer, 10% lymphoma, matched for body mass index [BMI]). Participants were randomised 1:1 to receive testosterone (Tostran 2% gel) or placebo for 26 weeks. A dose titration was performed after 2 weeks. The coprimary end points were trunk fat mass and SF36 Physical Functioning score (SF36-PF) at 26 weeks by intention to treat. At 26 weeks, testosterone treatment compared with placebo was associated with decreased trunk fat mass (-0.9 kg, 95% CI -1.6 to -0.3, p = 0.0073), decreased whole-body fat mass (-1.8 kg, 95% CI -2.9 to -0.7, p = 0.0016), and increased lean body mass (1.5 kg, 95% CI 0.9-2.1, p < 0.001). Decrease in fat mass was greatest in those with a high truncal fat mass at baseline. There was no treatment effect on SF36-PF or any other QoL scores. Testosterone treatment was well tolerated. The limitations of our study were as follows: a relatively short duration of treatment, only three cancer groups included, and no hard end point data such as cardiovascular events. Conclusions In young male cancer survivors with low-normal morning total serum testosterone, replacement with testosterone is associated with an improvement in body composition. Trial registration ISRCTN: 70274195, EudraCT: 2011-000677-31., Author(s): Jennifer S. Walsh 1, Helen Marshall 2, Isabelle L. Smith 2, Diana M. Greenfield 3, Jayne Swain 2, Emma Best 2, James Ashton 4, Julia M. Brown 2, Robert [...]
- Published
- 2019
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.